Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.21.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net loss from continuing operations $ (1,447,271) $ (3,534,466)
Net loss from discontinued operations (35,392) (4,070)
Adjustments to reconcile net loss to net cash used in operating activities:    
Loss/(gain) on sale of securities (12,649) 36,714
Loss on fair market value of equity investments 14,402
Accrued interest/dividends (24,324) (4,713)
Depreciation and amortization
Impairment of intangible assets
Changes in assets and liabilities    
Decrease in prepaid expenses 80,232 89,897
Increase/(decrease) in trade and other payables (1,368,151) 531,819
Increase in right-of-use liabilities 1,128
Cash Flows from Discontinued Operations (16,783) (324,969)
Net cash used in operating activities (2,482,947) (1,966,983)
Cash flows from investing activities:    
Short-term note receivable (1,800,000)
Purchases of marketable securities (15,269,129) (41,989)
Proceeds from sale of marketable securities 1,503,487 2,303,890
Net cash (used in)/provided by investing activities (15,565,642) 2,261,901
Cash flows from financing activities    
Net proceeds from the exercise of prepaid equity forward contracts for the purchase of common stock 77
Net cash provided by financing activities 77
Net increase/(decrease) in cash and restricted cash (18,048,589) 294,995
Cash and restricted cash at beginning of period 18,617,955 632,538
Cash and restricted cash at end of period 569,366 927,533
Supplemental cash flow information    
Interest
Income Taxes
Supplemental Schedule of Non-Cash Financing and Investing Activities    
Net unrealized losses on marketable securities (240,937)
Operating lease right-of-use asset obtained in exchange for lease obligation 306,706
Other assets - Investment in Oravax included in trade and other payables 1,500,000
Vendors [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 7,318
Cystron [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation 1,233,057
Director [Member] | Restricted Stock Units (RSUs) [Member]    
Adjustments to reconcile net loss to net cash used in operating activities:    
Share-based compensation $ 326,989 $ 1,302